Plus Therapeutics
PSTV
PSTV was delisted on the 31st of July, 2026.
22 hedge funds and large institutions have $872K invested in Plus Therapeutics in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
10% more funds holding
Funds holding: 20 → 22 (+2)
0.02% less ownership
Funds ownership: 0.04% → 0.02% (-0.02%)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
45% less capital invested
Capital invested by funds: $1.58M → $872K (-$707K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$80.9K |
| 2 |
Millennium Management
New York
|
+$52.9K |
| 3 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
+$10.7K |
| 4 |
VF
Virtu Financial
New York
|
+$5.73K |
| 5 |
Two Sigma Investments
New York
|
+$4.46K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$315K |
| 2 |
OCA
Otter Creek Advisors
Palm Beach Gardens,
Florida
|
-$147K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$21K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$9.87K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$7K |
PSTV Hedge Fund Activity: Q4 2022 in Review
22 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q4 2022, worth a combined $872K — down 45% from $1.58M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new PSTV positions and 3 closed out — a net gain of 2 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Schonfeld Strategic Advisors, opening a new position worth an estimated $80.9K. The largest seller was Parkman Healthcare Partners, cutting an estimated $315K.
- 22 institutional investors held Plus Therapeutics (PSTV) as of Q4 2022, up from 20 in Q3 2022.
- Funds reported $872K of Plus Therapeutics stock for Q4 2022, down 45% quarter-over-quarter.
- 5 funds opened new Plus Therapeutics positions in Q4 2022 and 3 closed out, a net change of +2 holders.
- The largest Plus Therapeutics buyer in Q4 2022 was Schonfeld Strategic Advisors, an estimated $80.9K added.
- The largest Plus Therapeutics seller in Q4 2022 was Parkman Healthcare Partners, an estimated $315K sold.
Based on aggregated 13F filings for Q4 2022.